Professor Jurgen Drews has been elected the new chairman ofthe Senior Advisory Group Biotechnology (SAGB). Last week'sgeneral assembly of SAGB unanimously elected him to succeedPeter Doyle, effective Jan. 1, 1994.

Drews is president of international research and developmentfor Hoffmann-La-Roche Inc. of Nutley, N.J., and a member ofthe Roche Group's Executive Committee. He is also a member ofthe faculty of medicine at the University of Heidelberg, wherehe teaches pharmacology.

SAGB, which exists to promote a supportive climate forbiotechnology in Europe, was set up in June 1989 by theEuropean Chemical Industry Federation. Doyle, head of R&D atZeneca, the health-care spinoff of ICI Pharmaceuticals Inc., hasbeen the group's chairman since it was formed. The group iscomposed of senior representatives from large companies thatare active in biotechnology. -- Michael Kenward

(c) 1997 American Health Consultants. All rights reserved.